Fibroblast extracellular matrix regulatory pathways (Fibroblast ECM pathways)

Fibroblast extracellular matrix (ECM) regulatory pathways encompass a complex network of signaling cascades and molecular interactions that govern the synthesis, degradation, and structural organization of the ECM. Fibroblasts are the primary cells responsible for maintaining tissue integrity; however, their dysregulation leads to the excessive deposition of collagen and other matrix proteins, a hallmark of fibrosis and the tumor microenvironment. Key components of these pathways include Transforming Growth Factor-beta (TGF-beta) signaling, integrin-mediated mechanotransduction, and the balance between Matrix Metalloproteinases (MMPs) and their inhibitors (TIMPs). In diseases such as idiopathic pulmonary fibrosis, systemic sclerosis, and various cancers, these pathways become constitutively active, driving pathological tissue stiffening and organ dysfunction. Therapeutic strategies often focus on inhibiting specific nodes within these pathways, such as tyrosine kinase receptors or connective tissue growth factors, to arrest or reverse fibrotic progression.

Other names

Fibroblast ECM remodelingFibroblast-mediated ECM homeostasisExtracellular matrix regulatory networkFibrotic signaling pathways

Drugs targeting these pathways typically act by inhibiting growth factor signaling (e.g., TGF-beta or PDGF inhibition), blocking integrin-mediated activation, or inhibiting enzymes responsible for ECM cross-linking and degradation to prevent pathological tissue stiffening and scarring.